GlassScriptPhysician profile
Susan Choe
NPI 1891157426
$2,401.09
in general payments reported to CMS, 2019-2025
30 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $47.36 · 2021: $587 · 2022: $417 · 2023: $1,013 · 2024: $337.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,349.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,349.23 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $580.48 | 2021-2024 | Vraylar, Ubrelvy, Synthroid |
| Novo Nordisk INC | $189.36 | 2021-2024 | Wegovy, Ozempic, Rybelsus |
| Lilly USA, LLC | $151.37 | 2020-2024 | Mounjaro |
| Pfizer INC. | $138.13 | 2021-2024 | |
| Merck Sharp & Dohme LLC | $116.70 | 2021-2023 | Vaxelis, Vaxneuvance, M-M-R II |
| Exact Sciences Corporation | $114.49 | 2023-2024 | Cologuard Collection Kit |
| Dexcom, INC. | $109.62 | 2022-2024 | Dexcom G6 Transmitter |
| Abbott Laboratories | $106.37 | 2021-2024 | Freestyle Libre 3, Freestyle Libre 2 |
| Bayer Healthcare Pharmaceuticals INC. | $105.80 | 2022-2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $100.53 | 2021-2023 | Trintellix |
| Amgen INC. | $72.20 | 2020-2022 | |
| Astellas Pharma US INC | $69.24 | 2021-2024 | Veozah |
| Xeris Pharmaceuticals, INC. | $68.52 | 2022-2023 | Gvoke Hypopen |
| Otsuka America Pharmaceutical, INC. | $60.74 | 2023-2024 | Rexulti, Abilify Asimtufii |
| Glaxosmithkline, LLC. | $56.13 | 2020-2024 | Arexvy, Shingrix, Bexsero |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $52.07 | 2022-2023 | |
| Amarin Pharma, INC. | $42.63 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $40.16 | 2021-2023 | Farxiga, Breztri |
| Sanofi Pasteur INC. | $33.44 | 2023 | |
| Esperion Therapeutics, INC. | $27.35 | 2021 | |
| Janssen Pharmaceuticals, INC | $23.36 | 2021 | |
| Medtronic, INC. | $22.49 | 2023 | Linq II |
| Phathom Pharmaceuticals, INC. | $20.60 | 2024 | Voquezna |
| Lucid Diagnostics INC. | $19.67 | 2024 | |
| Insulet Corporation | $18.32 | 2023 | Omnipod |
| Cranial Technologies, INC | $15.08 | 2021 | |
| Sanofi-Aventis U.S. LLC | $12.02 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $11.63 | 2021 | |
| Alfasigma USA, INC. | $11.35 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $11.24 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Susan Choe listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.